



Cara Therapeutics to Present at November Investor Conferences

November 8, 2018

STAMFORD, Conn., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors, today announced company management will present a company overview at three investor conferences in November:

Stifel 2018 Healthcare Conference (New York)

Date:Tuesday, November 13, 2018

Time:9:30 a.m. ET

Jefferies 2018 London Healthcare Conference (London, UK)

Date:Thursday, November 15, 2018

Time: 1:20 p.m. GMT+1 (8:20 a.m. ET)

Piper Jaffray 30th Annual Healthcare Conference (New York)

Date:Tuesday, November 27, 2018

Time:2:00 p.m. ET

A live audio webcast of each event can be accessed under "Events and Presentations" in the News & Investors section of the Company's website at www.CaraTherapeutics.com. Archived webcast recordings will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus and pain by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In Phase 2 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP), and is currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Additionally, in a recently completed Phase 2/3 trial in post-operative patients, I.V. CR845/difelikefalin has demonstrated reduction in moderate-to-severe pain, while also reducing the incidence and intensity of nausea and vomiting throughout the post-operative period.

The FDA has conditionally accepted KORSUVA™ as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

MEDIA CONTACT:

Annie Starr

6 Degrees

973-415-8838

astarr@6degreespr.com

INVESTOR CONTACT:

Michael Schaffzin

Stern Investor Relations, Inc.

212-362-1200

michael@sternir.com



Source: Cara Therapeutics, Inc.